The S&P/ASX All Ordinaries Index (ASX: XAO) is down 0.2% to 8,945.6 points at the time of writing on Tuesday.
Here are four ASX shares attracting buy ratings from the experts this week.
4 ASX shares with price growth ahead: brokers
Virgin Australia Holdings Ltd (ASX: VGN)
The Virgin Australia share price is $3.27, up 2.51% on Tuesday.
Ord Minnett has initiated coverage on Virgin Australia with a buy recommendation and a 12-month share price target of $3.65.
Virgin shares had their IPO just recently, returning to the ASX boards on 24 June. The IPO price was $2.90.
So far, the highest level that this ASX airline share has traded at is $3.41 (on its third day of trading).
In a new note, Ord Minnett said it believed Virgin could grow unit revenue at a faster rate than inflation due to weak oil prices and a structurally lower cost base post its administration.
The broker commented:
Virgin is well-placed in terms of fleet renewal requirements, its aircraft having an average age of 13 years, versus 16 years for arch-rival Qantas Airways (QAN) and a typical commercial aircraft life span of around 24 years.
It also has sufficient balance sheet capacity to fund any new aircraft and expansion.
Our expectation is for capital expenditure of $800–900 million over FY26–FY28 that would drive growth in seat numbers of 3% per annum.
Mesoblast Ltd (ASX: MSB)
Mesoblast shares are $2.52, up 1% today.
Bell Potter has maintained a speculative buy rating on this ASX biotech share and raised its 12-month price target from $3.40 to $3.50.
The change followed Mesoblast's latest cashflow update, which revealed US$13.2 million in gross sales for its flagship drug, Ryoncil.
Bell Potter said:
The major catalysts include revenue expansion from Ryoncil and the unrecognised value of a likely Accelerated Approval for Revascor in late-stage heart failure in CY26.
Catalyst Metals Ltd (ASX: CYL)
ASX gold share Catalyst Metals led the 5 best-performing All Ords stocks of FY25 with astounding share price growth of 362%.
Today, the ASX small-cap share is down 0.63% to $4.71.
In a new note, Morgans has upgraded Catalyst from an accumulate rating to a buy rating.
The broker said it has trimmed its 12-month share price target from $7.15 to $6.93 due to unit cost adjustments.
Ahead of the June quarter results we update our model to account for the recent Old Highway acquisition as well as adjustments to quarterly and FY26 forecasts.
With the majority of ASX gold producers reporting unit costs to the upper end of our forecasts, we adjust our cost estimates to reflect the broader upward trend across the gold space.
Regal Partners Ltd (ASX: RPL)
The Regal Partners share price is up 0.5% to $3.04.
Morgans has retained its buy rating on this ASX financial share with a price target of $3.55 after an update from the company.
In this note we update our earnings estimates to reflect updated 1HCY25 performance fees, 1HCY25 NPAT guidance of $40m and continued FUM growth through the Jun-25 quarter.
Trading at a PER of 13x (CY26), with a strong balance sheet and capacity to continue growing FUM, we retain our BUY rating with a price target of $3.55/sh.
